ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on developing and commercializing innovative treatments for neurological and rare diseases. The company maintains its global headquarters in San Diego, California, with substantial operations in Princeton, New Jersey and European… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ACADIA PHARMACEUTICALS INC does
In the company’s own words
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on developing and commercializing innovative treatments for neurological and rare diseases. The company maintains its global headquarters in San Diego, California, with substantial operations in Princeton, New Jersey and European headquarters in Zug, Switzerland. More information is available at www.acadia.com.
Acadia operates two core commercial franchises. The neurological disease franchise is anchored by NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The rare disease franchise centers on DAYBUE (trofinetide), the first and only approved treatment for Rett syndrome. These two commercial products generated net product sales of $1,071.5 million in 2025. DAYBUE STIX, a powder formulation for oral solution, received FDA approval in December 2025 and launched in the first quarter of 2026.
Beyond its commercial products, Acadia maintains a pipeline of product candidates addressing significant unmet medical needs. Remlifanserin (formerly ACP-204) is in Phase 2 development for Alzheimer's disease psychosis and Lewy Body Dementia psychosis. ACP-211, a deuterated R-norketamine, is in Phase 2 development for major depressive disorder. ACP-711, a GABAA-α3 positive allosteric modulator licensed from Saniona, is being developed for essential tremor with Phase 2 expected to begin in late 2026 or early 2027. ACP-271, a GPR88 agonist, is planned for Phase 1 studies in tardive dyskinesia and Huntington's disease. The company also maintains early-stage programs including ACP-2591 for Rett syndrome and Fragile X syndrome, and an antisense oligonucleotide program through collaboration with Stoke Therapeutics for SYNGAP1 syndrome.
Acadia's strategy emphasizes maximizing growth of NUPLAZID and DAYBUE in the United States while expanding trofinetide internationally, particularly in the European Union and Japan. The company is investing in four core strategic capabilities: precision medicine, data innovation through artificial intelligence and machine learning, globalization, and patient empowerment. Acadia holds approximately 49 issued U.S. patents and exclusive licenses to additional patents covering its product portfolio.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1070494
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ACADIA PHARMACEUTICALS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ACADIA PHARMACEUTICALS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ACADIA PHARMACEUTICALS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ACADIA PHARMACEUTICALS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ACADIA PHARMACEUTICALS INC's last four quarterly filings that the numbers alone won't show?”